BioWorld

Dec. 5, 2005

DNA-Methylating Enzyme Set To Become Biotech Workhorse

NeurogesX Adds $20M To Finish Pivotal Transacin Trials In Pain

Other News To Note

Inspire's Stock Tanks On Dry Eye Drug's Second Approvable Letter

The FDA dealt another blow to Inspire Pharmaceuticals Inc. with a second approvable letter for its investigational dry eye drug, diquafosol, shaving a third off the company's stock value Friday. (BioWorld Today) Read More

CMS' Demo Project 'Ain't What We Thought It Was,' Says Baird

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...